These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 5885064)

  • 1. Potential folic acid antagonists. I. The antitumor and folic acid reductase inhibitory properties of 6-substituted 2,4-diamino-5-arylazopyrimidines.
    Hampshire J; Hebborn P; Triggle AM; Triggle DJ; Vickers S
    J Med Chem; 1965 Nov; 8(6):745-9. PubMed ID: 5885064
    [No Abstract]   [Full Text] [Related]  

  • 2. Potential folic acid antagonists. 5. Synthesis and dihydrofolate reductase inhibitory activities of 2-amino-4,6-substituted-5-arylazopyrimidines.
    Chatterjee SS; Ludwig S; Moran JF; Triggle DJ; Wayne A
    J Med Chem; 1971 Dec; 14(12):1237-8. PubMed ID: 5116245
    [No Abstract]   [Full Text] [Related]  

  • 3. Potential folic acid antagonists. 3. The antitumor and folate reductase inhibitory properties of some irreversibly acting 6-N-substituted 2,4,6-triamino-5-(4-carbethoxyphenylazo)pyrimidines.
    Hampshire J; Hebborn P; Triggle AM; Triggle DJ
    J Med Chem; 1968 May; 11(3):583-8. PubMed ID: 5656500
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of some 5-arylazopyrimidines on the growth of Streptococcus faecalis.
    Sen D; Chaudhuri SD
    Indian J Biochem; 1970 Sep; 7(3):187-92. PubMed ID: 4252576
    [No Abstract]   [Full Text] [Related]  

  • 5. Potential folic acid antagonists. 6. Potential irreversible folate reductase inhibitors derived from 2,4-diamino-5-arylazopyrimidines.
    Chatterjee SS; Moran JF; Triggle DJ; Wayne A
    J Med Chem; 1971 Dec; 14(12):1244-5. PubMed ID: 5116249
    [No Abstract]   [Full Text] [Related]  

  • 6. Pyrimidine derivatives. 8. 5-Arylazopyrimidines and their inhibitory effects against transplantable mouse tumors.
    Israel M; Schlein HN; Maddock CL; Farber S; Modest EJ
    J Pharm Sci; 1966 Jun; 55(6):568-72. PubMed ID: 5924119
    [No Abstract]   [Full Text] [Related]  

  • 7. Nonclassical 2,4-diamino-5-aryl-6-ethylpyrimidine antifolates: activity as inhibitors of dihydrofolate reductase from Pneumocystis carinii and Toxoplasma gondii and as antitumor agents.
    Robson C; Meek MA; Grunwaldt JD; Lambert PA; Queener SF; Schmidt D; Griffin RJ
    J Med Chem; 1997 Sep; 40(19):3040-8. PubMed ID: 9301666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
    Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
    Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase inhibitors and antitumor agents: synthesis and biological activities of 2,4-diamino-5-methyl-6-[(monosubstituted anilino)methyl] pyrido[2,3-d]pyrimidines.
    Gangjee A; Adair O; Queener SF
    J Med Chem; 1999 Jul; 42(13):2447-55. PubMed ID: 10395486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 6-Substituted 2,4-diaminopyrido[3,2-d]pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents.
    Gangjee A; Zhu Y; Queener SF
    J Med Chem; 1998 Nov; 41(23):4533-41. PubMed ID: 9804692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential folic acid antagonists. 4. Synthesis and dihydrofolate reductase inhibitory activities of 2,4,6-triamino-5-arylazopyrimidines.
    Chatterjee SS; Garrison DR; Kaprove R; Moran JF; Triggle AM; Triggle DJ; Wayne A
    J Med Chem; 1971 Jun; 14(6):499-501. PubMed ID: 5091964
    [No Abstract]   [Full Text] [Related]  

  • 12. Synthesis of 5-methyl-5-deaza nonclassical antifolates as inhibitors of dihydrofolate reductases and as potential antipneumocystis, antitoxoplasma, and antitumor agents.
    Gangjee A; Shi J; Queener SF; Barrows LR; Kisliuk RL
    J Med Chem; 1993 Oct; 36(22):3437-43. PubMed ID: 8230134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
    Gangjee A; Adair OO; Queener SF
    J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2,4-diamino-5-deaza-6-substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical inhibitors of dihydrofolate reductases.
    Gangjee A; Vasudevan A; Queener SF; Kisliuk RL
    J Med Chem; 1996 Mar; 39(7):1438-46. PubMed ID: 8691474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural studies on bioactive compounds. 39. Biological consequences of the structural modification of DHFR-inhibitory 2,4-diamino-6-(4-substituted benzylamino-3-nitrophenyl)-6-ethylpyrimidines ('benzoprims').
    Richardson ML; Croughton KA; Matthews CS; Stevens MF
    J Med Chem; 2004 Jul; 47(16):4105-8. PubMed ID: 15267250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and antiproliferative activity of a series of novel 6-substituted pyrido[3,2-d]pyrimidines as potential nonclassical lipophilic antifolates targeting dihydrofolate reductase.
    Wang M; Yang J; Yuan M; Xue L; Li H; Tian C; Wang X; Liu J; Zhang Z
    Eur J Med Chem; 2017 Mar; 128():88-97. PubMed ID: 28152430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design and synthesis of lipophilic 2,4-diamino-6-substituted quinazolines and their evaluation as inhibitors of dihydrofolate reductases and potential antitumor agents.
    Gangjee A; Vidwans AP; Vasudevan A; Queener SF; Kisliuk RL; Cody V; Li R; Galitsky N; Luft JR; Pangborn W
    J Med Chem; 1998 Aug; 41(18):3426-34. PubMed ID: 9719595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. II. Synthesis and antitumor activity of N5-substituted glutamine analogs.
    Itoh F; Yoshioka Y; Yukishige K; Yoshida S; Wajima M; Ootsu K; Akimoto H
    Chem Pharm Bull (Tokyo); 1996 Aug; 44(8):1498-509. PubMed ID: 8795269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofolate reductase and thymidylate synthase and as potential antitumor agents.
    Gangjee A; Lin X; Kisliuk RL; McGuire JJ
    J Med Chem; 2005 Nov; 48(23):7215-22. PubMed ID: 16279780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of dihydrofolate reductase as antitumor agents: design, synthesis and biological evaluation of a series of novel nonclassical 6-substituted pyrido[3,2-d]pyrimidines with a three- to five-carbon bridge.
    Li H; Fang F; Liu Y; Xue L; Wang M; Guo Y; Wang X; Tian C; Liu J; Zhang Z
    Bioorg Med Chem; 2018 May; 26(9):2674-2685. PubMed ID: 29691154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.